Neurocrine Biosciences layoffs, on the record
Every job cut, severance charge and restructuring Neurocrine Biosciences reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from more than 1,400 to over 2,000.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | more than 1,400 | December 31, 2023 |
| 10-K for 2024 | approximately 1,800 | December 31, 2024 |
| 10-K for 2025 | over 2,000 | — |
Job cuts, severance and restructuring
Our summaryThe company adopted an Executive Severance Plan covering its executive officers, which sets severance benefits for covered executives on termination without cause or resignation for good reason. The plan replaced severance rights in prior employment agreements.
Word for word“The severance benefits provided pursuant to the Severance Plan supersede any severance benefits to which the Covered Employees were previously entitled, including pursuant to their respective employment agreements.” 10-K for 2024
Neurocrine Biosciences has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Neurocrine Biosciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.